A phase i study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer
作者： William R. Schelman , Tabraiz A. Mohammed , Anne M. Traynor , Jill M. Kolesar , Rebecca M. Marnocha
DOI: 10.1007/S10637-013-9999-7
关键词: Esophageal cancer 、 Oncology 、 Pharmacology 、 Cohort 、 Pegfilgrastim 、 Internal medicine 、 Neutropenia 、 Medicine 、 Cisplatin 、 Etoposide 、 Pharmacokinetics 、 Chemotherapy
摘要: … tolerated dose (MTD)/recommended phase 2 dose (RP2D), … cohort in patients with extensive-stage small cell lung cancer (ES-… neuroendocrine tumor, esophageal cancer and …
springer.com
sci-hub.se 参考文章(33)
U. Zangemeister-Wittke, A. Ziegler, Bcl-2 antisense therapy for cancer: the art of persuading tumour cells to commit suicide. Apoptosis. ,vol. 3, pp. 67- 74 ,(1998) , 10.1023/A:1009636722713
John Minna, Yoshihide Tsujimoto, Makoto Katsumata, Naohiko Ikegaki, Expression of bcl-2 in Small Cell Lung Carcinoma Cells Cancer Research. ,vol. 54, pp. 6- 8 ,(1994)
J. B. Fiveash, S. A. Chowdhary, D. Peereboom, T. Mikkelsen, L. B. Nabors, G. J. Lesser, M. R. Rosenfeld, X. Ye, S. A. Grossman, NABTT-0702: A phase II study of R-(-)-gossypol (AT-101) in recurrent glioblastoma multiforme (GBM) Journal of Clinical Oncology. ,vol. 27, pp. 2010- 2010 ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.2010
J. M. Adams, The Bcl-2 Protein Family: Arbiters of Cell Survival Science. ,vol. 281, pp. 1322- 1326 ,(1998) , 10.1126/SCIENCE.281.5381.1322
Dietmar Heiser, Verena Labi, Miriam Erlacher, Andreas Villunger, The Bcl-2 protein family and its role in the development of neoplastic disease Experimental Gerontology. ,vol. 39, pp. 1125- 1135 ,(2004) , 10.1016/J.EXGER.2004.04.011
Maria Q Baggstrom, Yingwei Qi, Marianna Koczywas, Athanassios Argiris, Elizabeth A Johnson, Michael J Millward, Sara C Murphy, Charles Erlichman, Charles M Rudin, Ramaswamy Govindan, Mayo Phase 2 Consortium, California Consortium, A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. Journal of Thoracic Oncology. ,vol. 6, pp. 1757- 1760 ,(2011) , 10.1097/JTO.0B013E31822E2941
Miranda Verschraagen, Epie Boven, Rita Ruijter, Kasper Van Der Born, Johannes Berkhof, Frederick H Hausheer, Wim JF Van Der Vijgh, Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites. Clinical Pharmacology & Therapeutics. ,vol. 74, pp. 157- 169 ,(2003) , 10.1016/S0009-9236(03)00150-4
Neal Ready, Nina A. Karaseva, Sergey V. Orlov, Alexander V. Luft, Olexandr Popovych, Jon T. Holmlund, Brian A. Wood, Lance Leopold, Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer Journal of Thoracic Oncology. ,vol. 6, pp. 781- 785 ,(2011) , 10.1097/JTO.0B013E31820A0EA6
Ute A. Sartorius, Peter H. Krammer, Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. International Journal of Cancer. ,vol. 97, pp. 584- 592 ,(2002) , 10.1002/IJC.10096
Benoit You, Brigitte Tranchand, Pascal Girard, Claire Falandry, Benjamin Ribba, Sylvie Chabaud, Pierre-Jean Souquet, Isabelle Court-Fortune, Véronique Trillet-Lenoir, Cécile Fournel, Michel Tod, Gilles Freyer, None, Etoposide pharmacokinetics and survival in patients with small cell lung cancer: A multicentre study Lung Cancer. ,vol. 62, pp. 261- 272 ,(2008) , 10.1016/J.LUNGCAN.2008.03.008